In melanoma and NSCLC, FAT1 can inhibit the tumor initiation ability of NSCLC cells by activating the Hippo signaling pathway, resulting in a significantly better survival outcome in patients with FAT1 mutations than the wild type and correlating with better immunogenicity and ICI efficacy. This evidence concerns the gene FAT1 and non-small cell lung carcinoma.